Mostrando 7 resultados de: 7
Filtros aplicados
Subtipo de publicación
Article(7)
Publisher
Cancer Immunology, Immunotherapy(1)
Frontiers in Oncology(1)
Gerontology(1)
Immunity and Ageing(1)
Immunology Letters(1)
Association among Terminally Differentiated T Cells, Frailty, and Dependency in a Group of Cuban Centenarians
ArticleAbstract: Introduction: Centenarians are considered a model of successful aging. Cuba exhibits one of the oldePalabras claves:Centenarians, Frailty, Immunosenescence, inflammation, terminally differentiated T cellsAutores:Añe-Kouri A.L., Bicet Y.D.L.C., González A., Lage Davila A., Ledón N., Llanez-Gregorich E., Luaces P.L.o., Pereira K., Ramos M.B., Rodríguez M., Rodríguez Y., Saavedra Hernández D., Silva A., Suárez G.M., Tania Crombet, Vidal A.Fuentes:scopusAssociations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer
ArticleAbstract: Aging is considered the single most significant risk factor for the majority of common malignances iPalabras claves:B cells, Epidermal growth factor, Pro-inflammatory cytokines, T cells, terminally differentiated T cellsAutores:Añe-Kouri A.L., Catala M., Cordero L., García Verdecia B., González A., Lage Davila A., Ledón N., Luaces P.L.o., Mazorra Z., Neninger Vinageras E., Pereira K., Saavedra Hernández D., Salomón E.E., Sánchez M.G., Suárez G.M., Tania CrombetFuentes:scopusAn anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: Report of three cases
ArticleAbstract: In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the diPalabras claves:CD6 molecule, coronavirus 2, covid-19, cytokine-release syndrome, IL-6, Itolizumab, Monoclonal antibody, SARS-COV-2Autores:Añe-Kouri A.L., Berrio J., Caballero A., Caballero J.A., Cepeda M., Cervantes J.B., Figueredo C., Filgueira L.M., Herrera C., Leon K., Lorenzo G., Lovelle O.A., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania CrombetFuentes:scopusAn anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
ArticleAbstract: Background: Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around thePalabras claves:covid-19, Cytokine release syndrome, IL-6, ItolizumabAutores:Añe-Kouri A.L., Betancourt J., Caballero A., Cepeda M., Chávez E., Filgueira L.M., Herrera C., Hidalgo C.J., Leon K., Lorenzo G., Manso L., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.Fuentes:scopusHIV-1 antiretroviral resistance in Cuba, 2009–2014
ArticleAbstract: INTRODUCTION By the end of 2017, there were more than 28,000 individuals living with HIV in Cuba, ovPalabras claves:Anti-HIV agents, antiretroviral therapy, Cuba, Drug resistance, Highly active antiretroviral therapy, hiv, Multiple drug resistanceAutores:Alemán-Campos Y., Alvarez-Gainza D., Álvarez-López A., Añe-Kouri A.L., Baños-Morales Y., Campos-Díaz J., Caturla-Fernández Y., Consuelo Beatriz Correa, Fonseca-Gómez C., Joanes-Fiol J., Kourí-Cardellá V., Limia-León C.M., Martínez-Montesinos Y., Ortega-González L.M., Pérez-Avila J., Pérez-Santos L., Pintos-Saavedra Y., Soto-Brito Y.Fuentes:scopusImmune, inflammatory and prothrombotic parameters in COVID-19 patients treated with an anti EGFR antibody
ArticleAbstract: SARS-CoV-2 infection causes a range of clinical presentations and induces changes in both innate andPalabras claves:covid-19, eGFR, inflammation, nimotuzumab, SARS-COV-2, T cellsAutores:Añe-Kouri A.L., Armada J.J., González Y.Z., Gregorich E.M.L., Londres H.D., Luaces P.L.o., Martínez A.H., Medel L., Mena J., Ramos M., Saavedra Hernández D., Sánchez Y.H., Tania Crombet, Troche M.Fuentes:scopusThymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy
ArticleAbstract: Lung cancer is the second cause of cancer related deaths worldwide. Chemotherapy and immunotherapy rPalabras claves:Biomodulina T, CIMAvax-EGF, naïve T cells, Non-small-cell lung cancer, PD-1, terminally differentiated T cellsAutores:Añe-Kouri A.L., Catala M., Díaz M., González A., Hernández J.d.l.C., Lage Davila A., Ledón N., Luaces P.L.o., Mazorra Z., Molina M.d.l.A., Peña Y., Pereira K., Portela S., Ramos R., Reyes M.C., Saavedra Hernández D., Suárez G.M., Tania CrombetFuentes:scopus